Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $275 to $305.
Ketamine for Parkinson’s Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine